Registries Service
Transform Real-World Data Into Actionable Evidence
Purpose-built oncology registries that deliver the longitudinal insights your stakeholders demand—faster, more flexible, and at a lower cost than traditional CROs
Fill Your Evidence Gaps With Real-World Insights Through Registries and Observational Research
Aptitude Health delivers custom‑designed, fit‑for‑purpose registries and observational research studies built from the ground up to answer your most critical strategic and evidence needs. Leveraging our Axess Network and more than 20 years of real-world evidence experience, we design, implement, and deliver registries and observational research programs that generate high‑quality real‑world insights aligned to your product development and commercialization objectives.
Two Registry Solutions, One Strategic Partner
Stand-Alone Observational Research Studies
Physician experience programs
Clinical utility studies
Observational studies
Disease and product registries
- Expedited recruitment leveraging our 6,500+ member Axess Network
- Listening to the needs of our customers and ensuring the right approach for their real-world research program
- Developing study materials and systems using nuanced real-world research tools and processes
- Operationalizing the program by leveraging our Axess Network for site identification and physician participation while managing all program aspects
- Delivering results to help our customers achieve their strategic, clinical, and commercial goals
iPROPEL Platform
One platform, many studies. iPROPEL Real-World Evidence Registry Platform: Precision Research in Oncology through Patient and provider Engagement Longitudinally
- Captures the patient journey from cancer screening through treatment and survivorship
- Developed independently by Aptitude Health with input from KOLs across the cancer treatment continuum
- Robust patient data from the entire health care ecosystem—EMR, lab/diagnostic, patient-reported
- Direct access to Axess Network members to offer research opportunities and market research
Why Leading Oncology Companies Choose Aptitude Health
Access to 5,800+ Community-Based Physicians
Direct access through our Axess Network to community-based oncologists and hematologists, who treat the majority of cancer patients–not just academic trialists.
25+ Years of Specialized Registry Expertise
Our team’s experience spans more than 25 years of observational research.
Fast, Flexible Study Start-Up
Purpose-built real-world evidence processes and platforms designed for speed and flexibility—not adapted from clinical trial infrastructure.
Cost-Effective With Lower Overhead
Transparent, flexible pricing with less overhead and minimal bureaucracy—we can do what CROs do for significantly less because we do not have their burden.
Unlike Traditional CROs...
Observational research is our core business, not 5–10% of an organization primarily focused on regulated clinical trials. We do not have the bureaucracy, overhead, or need to adapt clinical trial processes to fit real-world evidence needs. We are not trying to squeeze an square peg into a round hole—we are creating a peg that fits the existing space perfectly.
Addressing Your Critical Commercialization Challenges
Why isn't our product being used more?
Understand treatment adoption barriers and utilization patterns in real-world community practice settings where most patients receive care, not just academic medical centers.
How do we secure payor coverage and formulary placement?
Generate the comparative effectiveness and health economics data that insurance companies and payors require to support formulary decisions and reimbursement.
What can we tell physicians about real-world outcomes?
How do we respond to regulatory safety signals quickly?
Our flexible, purpose-built platforms enable rapid pivots—like transforming a registry into a safety data-collection program to address FDA concerns and prevent black box warnings.
How do we differentiate from me-too competitors?
Identify and validate the unique advantages of your therapy in specific patient subgroups and treatment sequences that clinical trials did not explore.